Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term RADIOTHERAPY. Found 24 abstracts

no pagination
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):686-718.   PMCID: No NIH funding
Lango MN, Andrews GA, Ahmad S, Feigenberg S, Tuluc M, Gaughan J, Ridge JA. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathological residual carcinoma and prognosis. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2009 Mar;31(3):328-37.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal of Clinical Oncology. 2009 Apr;27(10):1572-8.   PMCID: not NIH funded
Stathakis S, Roland T, Papanikolaou N, Li JS, Ma C. A Prediction Study on Radiation-induced Second Malignancies for IMRT Treatment Delivery. Technology in Cancer Research & Treatment. 2009 Apr;8(2):141-7.
Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. Journal of Clinical Oncology. 2009 Jan;27(1):100-5.   PMCID: PMC 2645095
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24.
Klein EE, Vicic M, Ma CM, Low DA, Drzymala RE. Validation of calculations for electrons modulated with conventional photon multileaf collimators. Physics in Medicine and Biology. 2008 Mar;53(5):1183-208.
McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Jan;112(1):134-41.
Rosenthal DI, Catalano PJ, Haller DG, Landry JC, Sigurdson ER, Spitz FR, Benson AB. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. International Journal of Radiation Oncology Biology Physics. 2008 Sep;72(1):108-13.
Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):353-60.
Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 2008 Dec;72(6):1298-302.
Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. Journal of Clinical Oncology. 2007 May;25(14):1898-907.
Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker AP. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncology. 2007 Oct;8(10):912-20.
Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer. 2007 Apr;109(8):1462-70.
Morrow M, O'Sullivan MJ. The dilemma of DCIS. Breast. 2007 Dec;16:S59-S62.
Roach M, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, Fisher B, Hanks G, Shipley WU, Pollack A, Sandler H, Watkins-Bruner D. Racial differences in cyp3a4 genotype and survival among men treated on radiation therapy oncology group (rtog) 9202: A phase III randomized trial. International Journal of Radiation Oncology Biology Physics. 2007 Sep;69(1):79-87.
Stathakis S, Li JS, Ma CC. Monte Carlo determination of radiation-induced cancer risks for prostate patients undergoing intensity-modulated radiation therapy. Journal of Applied Clinical Medical Physics. 2007 Jan;8(4):14-27.
Torres-Roca JF, DeSilvio M, Mora LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandier H, Pollack A. Activated STAT3 as a correlate of distant metastasis in prostate cancer: A secondary analysis of radiation therapy oncology group 86-10. Urology. 2007 Mar;69(3):505-9.
Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology. 2007 Jul;8(7):613-24.
Wang L, Li JS, Paskalev K, Hoban P, Luo W, Chen LL, McNeeley S, Price R, Ma C. Commissioning and quality assurance of a commercial stereotactic treatment-planning system for extracranial IMRT. Journal of Applied Clinical Medical Physics. 2006 Jan;7(1):21-34.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term RADIOTHERAPY

RADIOTHERAPY RADIATION-THERAPY CHEMOTHERAPY TRIAL THERAPY CARCINOMA radiotherapy PROSTATE-CANCER SURVIVAL CANCER ANDROGEN DEPRIVATION BREAST-CANCER FEASIBILITY PATTERNS CELL LUNG-CANCER TUMORS radiation therapy CHEMORADIOTHERAPY 3D-CRT IMRT LEUKEMIA RISK DOSE-RESPONSE ESCALATION RADICAL PROSTATECTOMY RISK QUALITY-OF-LIFE BEAM Monte Carlo RADIOCHEMOTHERAPY IMMEDIATE PHASE-II TRIAL DISEASE ENERGY NEOADJUVANT MALIGNANCIES PHASE-III Eastern Cooperative Oncology Group phase I SELECTIVE CYCLOOXYGENASE-2 INHIBITOR LUNG GROUP RTOG Second malignancy MULTIPLE FRACTIONS residual microscopic disease SQUAMOUS-CELL CARCINOMAS stereotactic IMRT Prostate cancer LOCAL RECURRENCE COLORECTAL-CARCINOMA DOSE-CALCULATION METHOD TRANSCRIPTION-3 symptom control STEREOTACTIC BODY RADIOTHERAPY COMBINATION CHEMOTHERAPY Oncology genetic polymorphisms TOMOTHERAPY TUMOR-REGRESSION TAMOXIFEN HAPLOTYPES Advanced endometrial cancer VALIDITY head and neck cancer COMBINED-MODALITY ADJUVANT CHEMOTHERAPY Cisplatin IONIZING-RADIATION prostate cancer 2ND CANCERS TOTAL SCALP IRRADIATION PREDICTORS Whole abdominal METASTATIC DISSEMINATION OROPHARYNGEAL CANCER CHEMORADIATION TOTAL MESORECTAL EXCISION LIVER METASTASES IRRADIATION LONG PELVIC LYMPHADENECTOMY PHASE-III TRIAL METASTASES BODY-COMPOSITION Conventional radiotherapy TOXICITY GEMCITABINE PLUS VINORELBINE patient preference neck LOCAL-CONTROL POLYMORPHISMS OVER-EXPRESSION DOSE-RATE BRACHYTHERAPY BIOCHEMICAL CONTROL oxaliplatin ACCURACY health-related quality of life ADVANCED HEAD Paclitaxel MODEL WOMEN Hormonal therapy SBRT THORACIC EFFICACY SUPPRESSION LEUKEMIA GROUP-B NODE-POSITIVE HEAD prognostic hypofractionation secondary malignancies Radiation therapy locoregional control CLINICAL PRESENTATION ASSISTED BONE-MINERAL DENSITY squamous cell carcinoma of the head and CARCINOMA-IN-SITU PAINFUL BONE METASTASES EXPRESSION ADENOCARCINOMA ABDOMINOPELVIC IRRADIATION INVASIVE BLADDER-CANCER BREAST-CONSERVING SURGERY neck dissection chemoradiation NECK-CANCER rectal cancer CLINICAL-TRIALS EXTERNAL-BEAM RADIOTHERAPY race INTENSITY-MODULATED MONTE-CARLO CALCULATIONS Cardiovascular mortality 8 GY PROGNOSTIC-FACTORS STAGE-III DCIS EORTC QLQ-C30 LOW-DOSE CARBOPLATIN PHOTON LAPAROSCOPIC PROSTATECTOMY dose-escalation study PROSTATECTOMY PERMANENT INTERSTITIAL BRACHYTHERAPY ADVANCED CERVICAL-CANCER CISPLATIN-BASED THERAPY EXTRACAPSULAR SPREAD PROSPECTIVE RANDOMIZED TRIAL LESIONS HORMONAL-THERAPY
Last updated on Friday, December 06, 2019